🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparative Analysis of Two Transforaminal Lumbar Interbody Fusion (TLIF) Procedures in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial

RecruitingNAAges 40 Years - 70 YearsAllThe Third Affiliated Hospital of Southern Medical…
NCT07588555 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Lumbar spinal stenosis (LSS), a common degenerative lumbar condition characterized by low back pain, leg pain, and neurogenic claudication, significantly impairs patients' quality of life. Its prevalence continues to rise with the aging population. For patients who do not respond to conservative treatment, surgical intervention remains a key therapeutic approach, with lumbar interbody fusion (LIF) being a commonly employed procedure. The technique has evolved from posterior lumbar interbody fusion (PLIF) to transforaminal lumbar interbody fusion (TLIF) and, more recently, to minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). Although MIS-TLIF can effectively reduce tissue trauma and complications, it still faces clinical challenges such as intraoperative visual blind spots and the potential for postoperative chronic back pain associated with reliance on conventional pe

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ranging from 40 to 70 years, irrespective of sex. * Presence of bilateral lower-limb pain and neurogenic claudication, with or without low back pain. * Preoperative computed tomography or magnetic resonance imaging confirming single-level lumbar spinal stenosis accompanied by grade II or higher lumbar spondylolisthesis and/or lumbar instability. * Persistent pain within 7 days prior to enrollment, with inadequate response to nonsurgical treatment for more than 3 months. * Willingness to provide written informed consent and ability to comply with the study protocol and visit schedule. Exclusion Criteria: * Patients with evidence of vascular claudication identified by lower-limb color Doppler ultrasound. * Patients with a history of previous lumbar spine surgery. * Coexistence of severe lumbar disc herniation, spinal deformity, spinal tumor, infection, or inflammatory diseases. * Pregnancy or lactation. * Presence of severe underlying medical conditions or psychiatric disorders that preclude tolerance of the procedure. * Known concurrent diseases considered by the investigator to preclude study entry. * Inability to comply with study assessments or complete questionnaires for any reason. * Patients deemed unsuitable for participation in this trial as judged by the investigator.
💊

What it tests

  • LUSE-TLIF
  • MIS-TLIF
📍

Where

1 site
The Third Affiliated Hospital of Southern Medical University
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy